The role of stem cell transplantation in the management of relapsed follicular lymphoma in the era of targeted therapies

Norman, Jane E.; Schouten, Harry C.; Dreger, Peter; Robinson, Stephen

doi:10.1038/s41409-018-0372-5

Cited by 12 publications

(9 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data supporting allogeneic hematopoietic SCT are even weaker, but the totality of evidence seems to suggests that it is beneficial only in ETF (and the earlier the relapse the greater the potential benefit). 74,75,81,82 However, it should be noted that data with the use of hematopoietic SCT consolidation in late relapses is understandably scarce. Finally, the chemosensitivity of the relapse is also likely to be a predictive biomarker (ie, the gain from allogeneic hematopoietic SCT over autologous or no SCT is likely to be greater in chemorefractory than chemosensitive disease but high-quality data to confirm this is unavailable).…”

Section: Hematopoietic Stem Cell Transplantmentioning

confidence: 99%

“…However, a majority of these patients received outdated front‐line strategies so the validity of the results today is unclear. Data supporting allogeneic hematopoietic SCT are even weaker, but the totality of evidence seems to suggests that it is beneficial only in ETF (and the earlier the relapse the greater the potential benefit) 74,75,81,82 . However, it should be noted that data with the use of hematopoietic SCT consolidation in late relapses is understandably scarce.…”

Section: Predictive Biomarkers In Follicular Lymphomamentioning

confidence: 99%

See 1 more Smart Citation

Precision medicine in follicular lymphoma: Focus on predictive biomarkers

Sorigué

Cañamero

Sancho

2020

Hematological Oncology

View full text Add to dashboard Cite

Current care for patients with follicular lymphoma (FL) offers most of them longterm survival. Improving it further will require careful patient selection. This review focuses on predictive biomarkers (ie, those whose outcome correlations depend on the treatment strategy) in FL, because awareness of what patient subsets benefit most or least from each therapy will help in this task. The first part of this review aims to summarize what biomarkers are predictive in FL, the magnitude of the effect and the quality of the evidence. We find predictive biomarkers in the setting of (a) indication of active treatment, (b) front-line induction (use of anthracyline-based regimens, CHOP vs bendamustine, addition of rituximab), (c) post-(front-line)induction (rituximab maintenance, radioimmunotherapy), and (d) relapse (hematopoietic stem cell transplant) and targeted agents. The second part of this review discusses the challenges of precision medicine in FL, including (a) cost, (b) clinical relevance considerations, and (c) difficulties over the broad implementation of biomarkers. We then provide our view on what biomarkers may become used in the next few years. We conclude by underscoring the importance of assessing the potential predictiveness of available biomarkers to improve patient care but also that there is a long road ahead before reaching their broad implementation due to remaining scientific, technological, and economic hurdles.

show abstract

Section: Hematopoietic Stem Cell Transplantmentioning

confidence: 99%

Section: Predictive Biomarkers In Follicular Lymphomamentioning

confidence: 99%

Precision medicine in follicular lymphoma: Focus on predictive biomarkers

Sorigué

Cañamero

Sancho

2020

Hematological Oncology

View full text Add to dashboard Cite

show abstract

“…Several prospective randomized and retrospective data around autologous stem cell transplantation in first-line setting found PFS improvement. [70][71][72][73][74] However, autologous stem cell transplantation as part of upfront management of patients with FL has been largely abandoned because of the lack of OS benefit. Additionally, due to availability of several new effective drugs with different innovative mechanisms of action, many clinicians prefer to observe their responding patients rather than to consolidate with autologous stem cell transplantation in upfront setting.…”

Section: Transplantationmentioning

confidence: 99%

“…With reduced-intensity conditioning approach, the observed relapse rate is under 20% 77 with 5-year PFS rates ranging from 50% to 85%. 74…”

Section: Transplantationmentioning

confidence: 99%

See 1 more Smart Citation

Diagnosis and management of follicular lymphoma: A comprehensive review

Dada

2019

European J of Haematology

View full text Add to dashboard Cite

Follicular Lymphoma (FL) is an indolent lymphoma and may have various clinical courses. Worldwide, FL is the second most common non-Hodgkin lymphoma (NHL) type after diffuse large B-cell lymphoma. In this review article, the author is discussing relevant diagnostic tools, prognostic factors, and updated study results on the management of patients with newly diagnosed and relapsed/refractory FL.Controversies in the treatment, maintenance therapy, stem cell transplantation, and novel treatment approaches will be comprehensively discussed. K E Y W O R D Sfollicular lymphoma, indolent lymphoma, low-grade lymphoma

show abstract